CN1698841A - 胡黄连总苷提取物的医药用途 - Google Patents
胡黄连总苷提取物的医药用途 Download PDFInfo
- Publication number
- CN1698841A CN1698841A CN 200510078446 CN200510078446A CN1698841A CN 1698841 A CN1698841 A CN 1698841A CN 200510078446 CN200510078446 CN 200510078446 CN 200510078446 A CN200510078446 A CN 200510078446A CN 1698841 A CN1698841 A CN 1698841A
- Authority
- CN
- China
- Prior art keywords
- rhizoma picrorhizae
- extract
- picrorhiza rhizome
- glycoside extract
- total glycoside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000284 extract Substances 0.000 title claims abstract description 73
- 241001483116 Neopicrorhiza scrophulariiflora Species 0.000 title claims abstract description 35
- 229930182470 glycoside Natural products 0.000 title claims abstract description 34
- 150000002338 glycosides Chemical class 0.000 title claims abstract description 34
- 208000006673 asthma Diseases 0.000 claims abstract description 30
- 239000003814 drug Substances 0.000 claims abstract description 25
- 201000010099 disease Diseases 0.000 claims abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 13
- 201000009961 allergic asthma Diseases 0.000 claims abstract 3
- 150000008131 glucosides Chemical class 0.000 claims description 40
- 229930182478 glucoside Natural products 0.000 claims description 38
- AKNILCMFRRDTEY-NUGKWEEESA-N [(1as,1bs,2s,5ar,6s,6as)-1a-(hydroxymethyl)-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,5a,6,6a-tetrahydro-1bh-oxireno[5,6]cyclopenta[1,3-c]pyran-6-yl] 4-hydroxy-3-methoxybenzoate Chemical compound C1=C(O)C(OC)=CC(C(=O)O[C@H]2[C@H]3[C@H]([C@@H](OC=C3)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@@]3(CO)O[C@H]32)=C1 AKNILCMFRRDTEY-NUGKWEEESA-N 0.000 claims description 27
- AKNILCMFRRDTEY-UHFFFAOYSA-N picroside II Natural products C1=C(O)C(OC)=CC(C(=O)OC2C3C(C(OC=C3)OC3C(C(O)C(O)C(CO)O3)O)C3(CO)OC32)=C1 AKNILCMFRRDTEY-UHFFFAOYSA-N 0.000 claims description 27
- JANLDILJJLTVDB-UHFFFAOYSA-N amphicoside Natural products C1=C(O)C(OC)=CC(C(=O)OCC23C(O2)C(O)C2C3C(OC3C(C(O)C(O)C(CO)O3)O)OC=C2)=C1 JANLDILJJLTVDB-UHFFFAOYSA-N 0.000 claims description 17
- AKNILCMFRRDTEY-UTPSRAKLSA-N COc1cc(ccc1O)C(=O)O[C@@H]1[C@@H]2O[C@]2(CO)C2C1C=CO[C@H]2O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O Chemical compound COc1cc(ccc1O)C(=O)O[C@@H]1[C@@H]2O[C@]2(CO)C2C1C=CO[C@H]2O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O AKNILCMFRRDTEY-UTPSRAKLSA-N 0.000 claims description 13
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 8
- QSPOERJDZBVCJH-UHFFFAOYSA-N Kutkin Natural products COc1cc(ccc1OC2OC(CO)C(O)C(O)C2O)C(O)(OC)C(=O)OC=Cc3ccccc3 QSPOERJDZBVCJH-UHFFFAOYSA-N 0.000 claims description 7
- XSIQHIDJSCQWBB-QHJBZRDQSA-N [(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] 3-methoxy-4-[(E)-3-phenylprop-2-enoyl]oxybenzoate dihydrate Chemical group O.O.COc1cc(ccc1OC(=O)\C=C\c1ccccc1)C(=O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XSIQHIDJSCQWBB-QHJBZRDQSA-N 0.000 claims description 7
- JANLDILJJLTVDB-NGOGGKKYSA-N [(1S,2S,4S,5S,6R,10S)-5-hydroxy-10-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,9-dioxatricyclo[4.4.0.02,4]dec-7-en-2-yl]methyl 4-hydroxy-3-methoxybenzoate Chemical compound COc1cc(ccc1O)C(=O)OC[C@]12O[C@H]1[C@@H](O)[C@@H]1C=CO[C@@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@H]21 JANLDILJJLTVDB-NGOGGKKYSA-N 0.000 claims description 6
- 229930182489 iridoid glycoside Natural products 0.000 claims description 6
- ZUKLFFYDSALIQW-MSUKCBDUSA-N Iridoid glycoside Chemical compound [H][C@]12CC[C@H](C(O)=O)[C@@]1([H])[C@H](OC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)OC=C2 ZUKLFFYDSALIQW-MSUKCBDUSA-N 0.000 claims description 5
- 230000002052 anaphylactic effect Effects 0.000 claims description 5
- QIIDATRCGITYRZ-UHFFFAOYSA-N Catalpol Natural products OCC1OC(OC2OC=CC3C(O)C(=C(CO)C23)O)C(O)C(O)C1O QIIDATRCGITYRZ-UHFFFAOYSA-N 0.000 claims description 3
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 3
- 201000010105 allergic rhinitis Diseases 0.000 claims description 3
- LHDWRKICQLTVDL-PZYDOOQISA-N catalpol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2[C@@]3(CO)O[C@H]3[C@@H](O)[C@@H]2C=CO1 LHDWRKICQLTVDL-PZYDOOQISA-N 0.000 claims description 3
- UXSACQOOWZMGSE-UHFFFAOYSA-N catalposide Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(OC(=O)C=3C=CC(O)=CC=3)C2C=CO1 UXSACQOOWZMGSE-UHFFFAOYSA-N 0.000 claims description 3
- LHDWRKICQLTVDL-UHFFFAOYSA-N methyl iridoid glycoside Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(O)C2C=CO1 LHDWRKICQLTVDL-UHFFFAOYSA-N 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 10
- 206010002198 Anaphylactic reaction Diseases 0.000 abstract description 6
- 230000036783 anaphylactic response Effects 0.000 abstract description 6
- 208000003455 anaphylaxis Diseases 0.000 abstract description 6
- 230000001684 chronic effect Effects 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 230000001741 anti-phlogistic effect Effects 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 210000002683 foot Anatomy 0.000 description 22
- 241001465754 Metazoa Species 0.000 description 19
- 239000000243 solution Substances 0.000 description 17
- 238000012360 testing method Methods 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 206010070834 Sensitisation Diseases 0.000 description 14
- 230000008313 sensitization Effects 0.000 description 14
- 230000008961 swelling Effects 0.000 description 14
- 239000007924 injection Substances 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 210000000627 locus coeruleus Anatomy 0.000 description 12
- 230000001629 suppression Effects 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 238000002386 leaching Methods 0.000 description 9
- 241000700199 Cavia porcellus Species 0.000 description 8
- 108010058846 Ovalbumin Proteins 0.000 description 8
- 241001494479 Pecora Species 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 210000003743 erythrocyte Anatomy 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- 229940092253 ovalbumin Drugs 0.000 description 8
- 239000005557 antagonist Substances 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 239000000048 adrenergic agonist Substances 0.000 description 6
- 229940126157 adrenergic receptor agonist Drugs 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- 239000000443 aerosol Substances 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 102000009660 Cholinergic Receptors Human genes 0.000 description 4
- 108010009685 Cholinergic Receptors Proteins 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000003862 glucocorticoid Substances 0.000 description 4
- 208000027866 inflammatory disease Diseases 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 239000008517 radix Trichosanthis Substances 0.000 description 4
- 230000000384 rearing effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 3
- 238000011047 acute toxicity test Methods 0.000 description 3
- 239000006286 aqueous extract Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000419 plant extract Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
- 206010048768 Dermatosis Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000015817 Infant Nutrition disease Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- 108010003541 Platelet Activating Factor Proteins 0.000 description 2
- 206010040914 Skin reaction Diseases 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 2
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical class NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000001088 anti-asthma Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940124623 antihistamine drug Drugs 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 210000000544 articulatio talocruralis Anatomy 0.000 description 2
- 239000000168 bronchodilator agent Substances 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 229960000265 cromoglicic acid Drugs 0.000 description 2
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 2
- 230000035617 depilation Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 230000035483 skin reaction Effects 0.000 description 2
- 231100000430 skin reaction Toxicity 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 244000296912 Ageratum conyzoides Species 0.000 description 1
- 235000004405 Ageratum conyzoides Nutrition 0.000 description 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 235000016535 Capraria biflora Nutrition 0.000 description 1
- LNSXRXFBSDRILE-UHFFFAOYSA-N Cucurbitacin Natural products CC(=O)OC(C)(C)C=CC(=O)C(C)(O)C1C(O)CC2(C)C3CC=C4C(C)(C)C(O)C(O)CC4(C)C3(C)C(=O)CC12C LNSXRXFBSDRILE-UHFFFAOYSA-N 0.000 description 1
- CVKKIVYBGGDJCR-SXDZHWHFSA-N Cucurbitacin B Natural products CC(=O)OC(C)(C)C=CC(=O)[C@@](C)(O)[C@@H]1[C@@H](O)C[C@]2(C)C3=CC[C@@H]4C(C)(C)C(=O)[C@H](O)C[C@@]4(C)[C@@H]3CC(=O)[C@@]12C CVKKIVYBGGDJCR-SXDZHWHFSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241001470703 Picrorhiza kurrooa Species 0.000 description 1
- 229940122117 Potassium channel agonist Drugs 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- AKYYFSOMEOHPPO-LQQBYVAQSA-N [(2r,3s,4s,5r,6s)-6-[[(1as,1bs,2s,5ar,6s,6as)-6-hydroxy-1a-(hydroxymethyl)-2,5a,6,6a-tetrahydro-1bh-oxireno[5,6]cyclopenta[1,3-c]pyran-2-yl]oxy]-3,4,5-trihydroxyoxan-2-yl]methyl (e)-3-(4-hydroxyphenyl)prop-2-enoate Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@H]1OC=C[C@H]2[C@H](O)[C@@H]3O[C@@]3([C@@H]12)CO)OC(=O)\C=C\C1=CC=C(O)C=C1 AKYYFSOMEOHPPO-LQQBYVAQSA-N 0.000 description 1
- XZGPUOQGERGURE-LUVHZPKESA-N [(2r,3s,4s,5r,6s)-6-[[(1as,1bs,2s,5ar,6s,6as)-6-hydroxy-1a-(hydroxymethyl)-2,5a,6,6a-tetrahydro-1bh-oxireno[5,6]cyclopenta[1,3-c]pyran-2-yl]oxy]-3,4,5-trihydroxyoxan-2-yl]methyl (e)-3-phenylprop-2-enoate Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@H]1OC=C[C@H]2[C@H](O)[C@@H]3O[C@@]3([C@@H]12)CO)OC(=O)\C=C\C1=CC=CC=C1 XZGPUOQGERGURE-LUVHZPKESA-N 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960004495 beclometasone Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 150000001904 cucurbitacins Chemical class 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- PIGAXYFCLPQWOD-UHFFFAOYSA-N dihydrocucurbitacin I Natural products CC12C(=O)CC3(C)C(C(C)(O)C(=O)CCC(C)(O)C)C(O)CC3(C)C1CC=C1C2C=C(O)C(=O)C1(C)C PIGAXYFCLPQWOD-UHFFFAOYSA-N 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- SCIGYBYAZUFDLA-YRWPAIAPSA-N globularin Natural products OC[C@H]1O[C@@H](O[C@@H]2OC=C[C@H]3[C@H](O)[C@@H]4O[C@]4(COC(=O)C=Cc5ccccc5)[C@@H]23)[C@H](O)[C@@H](O)[C@@H]1O SCIGYBYAZUFDLA-YRWPAIAPSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 150000008145 iridoid glycosides Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229930182487 phenolic glycoside Natural products 0.000 description 1
- 150000007950 phenolic glycosides Chemical class 0.000 description 1
- KEUKDVIGAVVGLF-RUYHYXBRSA-N picroside I Natural products OC[C@]12O[C@H]1[C@@H]3O[C@@H](O[C@@H]4O[C@H](COC(=O)C=Cc5ccccc5)[C@@H](O)[C@H](O)[C@H]4O)C=C[C@@H]3[C@H]2O KEUKDVIGAVVGLF-RUYHYXBRSA-N 0.000 description 1
- AKYYFSOMEOHPPO-UHFFFAOYSA-N picroside IV Natural products C12C3(CO)OC3C(O)C2C=COC1OC(C(C(O)C1O)O)OC1COC(=O)C=CC1=CC=C(O)C=C1 AKYYFSOMEOHPPO-UHFFFAOYSA-N 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
组别 | 动物数(n) | 剂量(mg/kg) | 引喘潜伏期(秒) | 抽搐动物数(只) |
对照 | 10 | - | 61.8±32.5 | 10/10 |
西藏胡黄连总苷提取物 | 10 | 200 | 150.5±89.8* | 9/10 |
组别 | 动物数 | 剂量mg/kg | 不同血清浓度蓝斑直径(cm) | |
(只) | 1∶30 | 1∶40 | ||
空白对照 | 10 | 水 | 1.48±0.21 | 0.94±0.26 |
西藏胡黄连总苷提取物 | 10 | 300.0 | 0.96±0.21* | 0.64±0.20* |
抑制率% | 35.1 | 31.9 |
组别 | 动物数(只) | 剂量(mg/kg) | 足肿胀程度(g) | 抑制率(%) |
空白对照组 | 9 | 水 | 2.51±0.73 | --- |
西藏胡黄连总苷提取物 | 10 | 400.0 | 1.74±0.74* | 30.68 |
组别 | 动物数(n) | 剂量(mg/kg) | 引喘潜伏期(秒) | 抽搐动物数(只) |
对照 | 10 | - | 63.7±33.6 | 10/10 |
印度胡黄连总苷提取物 | 10 | 200 | 158.5±91.8* | 9/10 |
组别 | 动物数 | 剂量mg/kg | 不同血清浓度蓝斑直径(cm) | |
(只) | 1∶30 | 1∶40 | ||
空白对照 | 10 | 水 | 1.51±0.23 | 0.95±0.23 |
印度胡黄连总苷提取物 | 10 | 300.0 | 0.93±0.22* | 0.62±0.21* |
抑制率% | 38.4 | 34.7 |
组别 | 动物数(只) | 剂量(mg/kg) | 足肿胀程度(g) | 抑制率(%) |
空白对照组 | 9 | 水 | 2.57±0.76 | --- |
印度胡黄连总苷提取物 | 10 | 400.0 | 1.68±0.70* | 34.63 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200510078446 CN1698841A (zh) | 2005-06-13 | 2005-06-13 | 胡黄连总苷提取物的医药用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200510078446 CN1698841A (zh) | 2005-06-13 | 2005-06-13 | 胡黄连总苷提取物的医药用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1698841A true CN1698841A (zh) | 2005-11-23 |
Family
ID=35475195
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200510078446 Pending CN1698841A (zh) | 2005-06-13 | 2005-06-13 | 胡黄连总苷提取物的医药用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1698841A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1904054A4 (en) * | 2005-05-30 | 2008-12-31 | Korea Res Inst Of Bioscience | PHARMACEUTICAL COMPOSITION CONTAINING PSEUDOLYSIMACHIONE LONGIFOLIUM EXTRACT AND CATALPOL DERIVATIVES ISOLATED THEREFROM, WITH ANTI-INFLAMMATORY, ANTI-ALLERGIC AND ANTI-ASTHMATIC ACTION |
US8455541B2 (en) | 2005-05-30 | 2013-06-04 | Korea Research Institute Of Bioscience And Biotechnology | Pharmaceutical composition comprising an extract of pseudolysimachion longifolium and the catalpol derivatives isolated therefrom having antiinflammatory, antiallergic and antiasthmatic activity |
-
2005
- 2005-06-13 CN CN 200510078446 patent/CN1698841A/zh active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1904054A4 (en) * | 2005-05-30 | 2008-12-31 | Korea Res Inst Of Bioscience | PHARMACEUTICAL COMPOSITION CONTAINING PSEUDOLYSIMACHIONE LONGIFOLIUM EXTRACT AND CATALPOL DERIVATIVES ISOLATED THEREFROM, WITH ANTI-INFLAMMATORY, ANTI-ALLERGIC AND ANTI-ASTHMATIC ACTION |
US8455541B2 (en) | 2005-05-30 | 2013-06-04 | Korea Research Institute Of Bioscience And Biotechnology | Pharmaceutical composition comprising an extract of pseudolysimachion longifolium and the catalpol derivatives isolated therefrom having antiinflammatory, antiallergic and antiasthmatic activity |
US8974837B2 (en) | 2005-05-30 | 2015-03-10 | Korea Research Institute Of Bioscience And Biotechnology | Pharmaceutical composition comprising an extract of Pseudolysimachion longifolium and the catalpol derivatives isolated therefrom having antiinflammatory, antiallergic and antiasthmatic activity |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100522983C (zh) | 梓醇及其同系物的医药用途 | |
CN1843399A (zh) | 一种治疗良性前列腺增生的药物及其制备方法 | |
CN1179729C (zh) | 以草药为主要成分的稳定的抗癌组合物及其制造方法 | |
CN1698841A (zh) | 胡黄连总苷提取物的医药用途 | |
CN100367977C (zh) | 一种返魂草提取物,它的提取方法及制剂 | |
CN1724014A (zh) | 威灵仙总皂苷提取物、其制备方法及其在制备药物中的用途 | |
CN114404462B (zh) | 一种组合物及其在制备具有治疗胃损伤和/或胃溃疡作用的药物中的应用 | |
CN1468601A (zh) | 胡黄连苷ⅱ-一种用于治疗、预防过敏性炎性疾病的新药 | |
CN100349590C (zh) | 地黄茎叶及其提取物抗哮喘和抗过敏的医药用途 | |
CN100349589C (zh) | 地黄提取物在制备抗哮喘和抗过敏的药物中的用途 | |
CN1989990A (zh) | 一种治疗勃起功能障碍的药物及其制备方法 | |
CN1795882A (zh) | 梓属植物及其提取物抗过敏性疾病的医药用途 | |
CN1278709C (zh) | 一种治疗感冒的药物及其制备方法 | |
CN1155380C (zh) | 氧化苦参碱在制备治疗溃疡性结肠炎药物中的应用 | |
CN104095843B (zh) | 牛蒡子苷元在制备治疗消化道溃疡性疾病药物中的应用 | |
CN101015622A (zh) | 地黄总苷提取物的医药用途及制备方法 | |
CN1695708A (zh) | 复方龙血竭制剂及其制备工艺与应用 | |
CN1634118A (zh) | 含有多糖聚阴离子锌盐的抗病毒制剂及其制备方法 | |
CN1265806C (zh) | 治疗风湿病的药物组合物 | |
CN1471914A (zh) | 防治由sars病毒引起的非典型肺炎的药物和应用及其制备方法 | |
CN1465389A (zh) | 大青龙汤药物制剂及其制备 | |
CN1429834A (zh) | 猪牙皂总皂苷及其制备方法与其在制备药物中的应用 | |
CN1500505A (zh) | 一种治疗小儿病毒性肺炎的药物组合物及其制备方法 | |
CN1989995A (zh) | 一种治疗良性前列腺增生的药物及其制备方法 | |
CN1403129A (zh) | 一种用于戒毒抗复吸的中药制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20061020 Address after: Beijing Changping District Shahe Town Exhibition Road 27 Applicant after: China Medicament Research & Development Center Co., Ltd. Address before: Beijing, Changping, Shahe Exhibition Road No. 27 Applicant before: Luo Hesheng |
|
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Du Supeng Document name: Notification before expiration of term |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Du Supeng Document name: Notification of the application for patent for invention to go through the substantive examination procedure |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20051123 |